Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Safety To Be Evaluated In Senate Health Committee Hearings

This article was originally published in The Tan Sheet

Executive Summary

The Senate Health Committee will convene March 1 and 3 to hold hearings on prescription drug safety issues

You may also be interested in...



Naproxen Could Serve As NSAID Safety Trial Standard, Advisory Panel Says

Naproxen should be excluded from any cardiovascular warnings required for NSAIDs, FDA's joint panel on COX-2 safety recommended Feb. 18

FDA Drug Safety Board Keeps Oversight In House, Online

FDA's Drug Safety Oversight Board (DSB) will seek to address the agency's safety issues on an internal basis

FDA Postmarketing Safety Upgrades Gain Momentum In Congress

A new FDA drug safety office would have jurisdiction over OTC drug marketing under a proposal from Sen. Chris Dodd (D-Conn.)

Related Content

Topics

UsernamePublicRestriction

Register

PS097893

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel